EUVIMEDEUVIMED entdecken
Open Access

Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience

Carolina Solis-Herrera, Michael P Kane, Curtis Triplitt iD

Clinical Diabetes · 01.01.2024 · 42 (1) · 74-86

DOI: 10.2337/cd22-0118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Diabetes, online erschienen am 22.08.2023. Verfasst von Carolina Solis-Herrera und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, University of Texas Health Science Center, San Antonio, TX. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral administration of peptide therapeutics faces challenges because of the distinct environment of the gastrointestinal tract. An oral formulation of semaglutide, a glucagon-like peptide 1 receptor agonist, was approved by the U.S. Food and Drug Administration in 2019 as a peptide therapy for the treatment of type 2 diabetes. Oral semaglutide uses sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) technology to enhance the absorption of semaglutide in the stomach and protect it from degradation by gastric enzymes. This article presents a summary of studies investigating SNAC technology as an absorption enhancer for a number of molecules and, in particular, explores how SNAC, once coformulated with oral semaglutide, facilitates increased absorption and bioavailability. Practical advice and dispensing information for pharmacists is also provided.

Autor:innen und Institutionen

  • Division of Diabetes, University of Texas Health Science Center, San Antonio, TX.
  • Division of Endocrinology, University of Texas Health Science Center, San Antonio, TX.
  • Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY.

ORCID-Profile: Curtis Triplitt

Zitieren

APA

Solis-Herrera, C., Kane, M. P., & Triplitt, C. (2024). Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience. Clinical Diabetes, 42(1), 74-86. https://doi.org/10.2337/cd22-0118

Vancouver

Solis-Herrera C, Kane MP, Triplitt C. Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience. Clinical Diabetes. 2024;42(1):74-86. doi:10.2337/cd22-0118

BibTeX
@article{SolisHerrera2024,
  author = {Solis-Herrera, Carolina and Kane, Michael P and Triplitt, Curtis},
  title = {Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience},
  journal = {Clinical Diabetes},
  year = {2024},
  volume = {42},
  number = {1},
  pages = {74--86},
  doi = {10.2337/cd22-0118}
}
Kostenlos starten →